GCCL to Present Research Findings on RSV Focus Reduction Neutralization Test at WVC

Global clinical trial sample analysis organization GCCL announced on March 24 that it will participate in the 'World Vaccine Congress 2026 (WVC 2026)', which will be held in Washington, DC, USA, from March 30 to April 2, 2026. GCCL will operate an exhibition booth and present its latest research findings through a poster presentation at the event.

At this event, GCCL will present a poster on the theme of "Development and Optimization of Focus Reduction Neutralization Test (FRNT) for Evaluating Neutralizing Antibody Titers against Respiratory Syncytial Virus (RSV)."

The analysis system developed by the research team led by Dr. Choi Hyunwook of GCCL (including Senior Researcher Lee Hyojeong) was introduced to address the limitations of existing neutralizing antibody measurement methods. By establishing an 'automation-based FRNT analysis system' that automatically interprets infection traces using dedicated equipment and quantifies the results, the system dramatically improves the objectivity and reproducibility of the analysis.

The research team validated the test performance using the World Health Organization (WHO) international standard material and the approved antibody therapeutic 'Palivizumab.' According to the company, this analytical method can be used in various stages of RSV vaccine and therapeutic development, including candidate screening, efficacy evaluation, and clinical immunogenicity analysis.

GCCL stated that, given the high global CRO dependency and limited domestic commercial service infrastructure for RSV FRNT-related services, the company plans to support domestic and Asian developers in securing immunogenicity evaluation data by establishing an FRNT-based analysis system.

Additionally, GCCL will operate an exclusive exhibition booth during WVC 2026, showcasing its integrated clinical trial sample analysis and analytical method development capabilities for vaccine and therapeutic development. The company also plans to actively seek business collaboration opportunities through business meetings with global vaccine and pharmaceutical companies participating in the event.

GCCL CEO Cho Kwangoo stated, "GCCL will expand discussions on joint projects and service collaborations with overseas partners based on our clinical trial analysis capabilities required in vaccine and therapeutic development, and we will translate these into tangible contracts. Through our exhibition booth and poster presentation, we will further refine our analytical offerings to meet global client needs and strengthen our position as a trusted testing partner in the APAC region, building a foundation for long-term collaboration."

This content was produced with the assistance of AI translation services.